135-140 Differential TAG-72 epitope expression in breast cancer and lymph node metastases: A marker of a more aggressive phenotype

Oncology Reports

Volumn 9, Issue 1, 2002, Pages 135-140

  Galietta, Annamaria ^a   Pizzi, Claudia ^a   Pettinato, Guido ^a   Limite, Gennaro ^a   Sgambato, Alessandro ^b   Lamberti, Maria ^a   Muraro, Raffaella ^c   Formisano, Cesare ^a   Pensabene, Matilde ^a   Bianco, Angelo Raffaele ^a   Mariani Costantini, Renato ^c   Contegiacomo, Alma ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Breast cancer; Cell kinetics; Lymph node metastasis; TAG 72; Tumour associated antigen

Indexed keywords

B72.3 ANTIBODY; CANCER ANTIBODY; DIAGNOSTIC AGENT; EPITOPE; GLYCOPROTEIN; THYMIDINE; TUMOR ANTIGEN; TUMOR ASSOCIATED ANTIGEN 72; TUMOR MARKER; TUMOR-ASSOCIATED ANTIGEN 72;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST TUMOR; CANCER INVASION; CANCER STAGING; COLLOID CARCINOMA; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNOLOGY; LUNG CARCINOMA; LYMPH NODE; LYMPH NODE METASTASIS; MEDULLARY CARCINOMA; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, INFILTRATING DUCT; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; EPITOPES; FEMALE; GLYCOPROTEINS; HUMAN; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; THYMIDINE; TUMOR MARKERS, BIOLOGICAL;

EID: 0036133918     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Nuti M, Teramoto YA, Mariani-Costantini R, Horan Hand P, Colcher D and Schlom J: A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumour-associated antigen in human mammary carcinoma cell populations. Int J Cancer 29: 539-545, 1982. (Pubitemid 12114628)
2. Horan Hand P, Nuti M, Colcher D and Schlom J: Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell population using monoclonal antibodies to tumour-associated antigens. Cancer Res 44: 728-735, 1983. (Pubitemid 13193872)
3. Thor A, Ohuchi N, Szpak CA, Johnston WW and Schlom J: The distribution of oncofoetal antigen TAG 72 defined by monoclonal antibody B72.3. Cancer Res 46: 3118-3124, 1986. (Pubitemid 16074337)
4. Muraro R, Kuroki D, Wunderlich D, Poole DJ, Colcher D, Thor A, Greiner JW, Simpson J, Molinolo A, Nogushi P and Schlom J: Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumour-associated glycoprotein 72 antigen. Cancer Res 48: 4588-4596, 1988.
5. Molinolo A, Simpson JF, Thor A and Schlom J: Enhanced tumour binding using immunohistochemical analyses by second generation anti-tumour-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 50: 1291-1298, 1990. (Pubitemid 20084025)
6. Schlom J, Eggensperger D, Colcher D, Molinolo A, Houchens D, Miller LS, Hinkle G and Siler K: Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 52: 1067-1072, 1992.
7. Contegiacomo A, Alimandi M, Muraro R, Pizzi C, Calderopoli R, De Marchis L, Sgambato A, Pettinato G, Petrella G, De Filippo MR and Mariani-Costantini R: Expression of epitopes of the tumour-associated glycoprotein 72 and clinicopathological correlations in mammary carcinomas. Eur J Cancer 30A: 813-820, 1994. (Pubitemid 24217339)
8. Greenson JK, Isenhart CE, Rice R, Mojzisik C, Houchens D and Martin EW: Identification of occult micrometastases in pericolic lymph nodes of Dukes' B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Cancer 73: 563-569, 1994. (Pubitemid 24046594)
9. Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, Arcuri R, Abbolito MR, Casale V, Pericoli MN, Vecchione A, Casciani CU, Greiner JW and Schlom J: Correlation between tumour-associated glycoprotein 72 mucin levels in tumour and serum of colorectal patients as measured by the quantitative CA72-4 immunoassay. Cancer Res 56: 5293-5298, 1996. (Pubitemid 26383050)
10. Pizzi C, Sgambato A, De Laurentiis M, Limite G, Panico L, Pettinato G, Muraro R, Tauchmanova L, Galietta A, Bianco AR, Mariani-Costantini R and Contegiacomo A: TAG-72 expression and clinical outcome in primary breast cancer. Oncol Rep 6: 1399-1403, 1999.
11. Santos AD, Kashmiri SVS, Horan Hand P, Schlom J and Padlan EA: Generation and characterization of a single gene-encoded single-chain-tetravalent antitumour antibody. Clin Cancer Res 5: 3118s-3123s, 1999. (Pubitemid 29493904)
12. I31I-labeled CC-49 for therapy in a colon cancer xenograft model. Clin Cancer Res 5: 3153s-3159s, 1999.
13. Pavlinkova G, Beresford GW, Booth BJ, Batra SK and Colcher D: Pharmacokinetics and biodistribution of engineerd single-chain antibody constructs of Mab CC49 in colon carcinoma xenografts. J Nucl Med 40: 1536-1546, 1999. (Pubitemid 29428939)
14. 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res 2: 1811-1818, 1996.
15. Murray JL, Macey DJ, Grant EJ, Rosenblum MG, Kasi LP, Zhang HZ, Katz RL, Riegel PT, LeBherz D, Bhadkamkar V, Greiner JW, Schlom J and Podoloff DA: Enhanced TAG-72 expression and tumour uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following - interferon treatment. Cancer Res 55: 5925-5928, 1995.
16. 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. Clin Cancer Res 3: 1547-1555, 1997.
17. Schmolling J, Reinsberg J, Wagner U and Krebs D: Anti-TAG-72 antibody B72.3 - immunological and clinical effects in ovarian carcinoma. Hybridoma 16: 53-58, 1997. (Pubitemid 27148690)
18. Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L and Kavanagh JJ: Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res 5: 953-961, 1999. (Pubitemid 29233207)
19. 131I- labeled high affinity CC-49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res 5: 3254s-3258s, 1999.
20. Lottich SC, Johnston WW, Szpak CA, Delong ER, Thor A and Schlom J: Tumour-associated antigen TAG-72: correlation of expression in primary and metastatic breast carcinoma lesions. Breast Cancer Res Treat 6: 49-56, 1985. (Pubitemid 15241229)
21. Lamki LM, Buzdar AU, Singletary SE, Rosenblum MG, Bhadkamkar V, Esparza L, Podoloff DA, Zukiwski A, Hortobagyi GN and Murray JL: Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. J Nucl Med 37: 1326-1332, 1991.
22. Mangili F, Sassi I, Di Rocco M, Leone BE, Garancini P and Santambrogio G: Breast carcinoma detection with a combination of radiolabeled monoclonal antibodies. Promising results from immunohistochemistry studies. Cancer 78: 2334-2339, 1996. (Pubitemid 26392832)
23. 131I-labeled monoclonal antibody B72.3. Nucl Med Biol 25: 251-260, 1998.
24. WHO: Histological Typing of Breast Cancer. 2nd edition. Geneva, World Health Organization, 1981.
25. Bloom HJG and Richardson WW: Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377, 1957.